Until now, all alternative drugs to anticovid vaccines have been the object of denigration, negative fact checking, derision and their effectiveness has been attributed to “delirium no vax”.
But there is a drug that these days escapes the usual treatment of media denial against possible alternative drug therapies.
The drug is called Anakinra.
All the newspapers usually aligned with vaccinopensiero are praising it.
Some examples from the last days.
“I was going to die and then …” Anakinra case in Out of the box, why the anti-Covid drug has not yet been approved? “, Headlines Il Tempo on September 14th.
Open online echoes him on September 16:
“How (and when) the drug Anakinra against Coronavirus works”, adding “The drug combined with other drugs reduces mortality and hospitalization times in severe forms of the disease”.
It’s still:
“What is Anakinra, an anti-inflammatory that reduces deaths and hospitalizations from Covid. Rasi:” Promising “, headlines Huffingtonpost (September 15)
Fanpage advertises it, again on September 15, thus presenting the study in Nature:
“The drug Anakinra reduces the mortality of serious Covid patients by up to 80%: the study in Nature”
In short, a plebiscite, without the various Bassetti, Pregliasco or Crisanti having spent a few words on TV to respond to Anakinra and demolish the heresy that there may be a drug that cures Covid (anathema!), Also because no journalist has made a single question about it.
Because?
There is something wrong.
Let’s see who is behind it.
1) the company that produces the drug, SOBI (Swedish Orphan Biovitrum), for a system of Chinese boxes, seems to be controlled by the same investment funds that also run other pharmaceutical companies (see Vanguard) https://it.finance. yahoo.com/quote/SOBI.ST?p=SOBI.ST&.tsrc=fin-srch
2) the price of the drug seems to be very high, around 365 euros for each patient.
3) on 2 September the acquisition of SOBI by two companies is announced: https://www.pharmastar.it/news//business/sobi-riceve-offer-di-cquiring-per-81-mld-da -fondo-americano-36210 and since that day the title has been on the rise.
Sobi pubblica con enfasi lo studio: Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumonia https://it.finance.yahoo.com/news/nature-medicine-publishes-positive-phase-120000927.html
“Swedish Orphan Biovitrum (SOBI) reports that it has received a takeover offer for $ 8.1 billion (SEK 69.4 billion) from US private equity firm Advent International and Aurora Investment, a subsidiary of the group GIC.
Following the news of the offer, SOBI’s shares rose 24.2% to 238 crowns, representing a premium of approximately 34.5% at its August 25 closing price of 174.70 crowns on the Stockholm Nasdaq. .
Investor AB and Fjärde AP-Fonden, with stakes in SOBI of approximately 36.45% and 6.96% respectively, have separately decided to accept the offer, says SOBI.
In fact, Advent and GIC said the company will benefit from the stock market exit because it needs substantial investment to develop its new drugs.
The company was at a loss.
Sobi’s hemophilia drug business came under price pressure and the company ran into debt after a series of acquisitions.
In the midst of the pandemic, the pharmaceutical companies that produced drug therapies for diseases other than covid and especially for rare diseases suffered immense losses.
SOBI, which sells drugs for hemophilia, autoimmune diseases, metabolic diseases and cancer treatments, has run up debt after debt.
“During the pandemic, SOBI suffered from a weakening demand for its drugs as health care focused on COVID-19.
The European medicines regulator (EMA) is evaluating SOBI’s arthritis drug anakinra to treat COVID-19 in adults with pneumonia who are at risk for severe respiratory failure. “
(Source https://www.pharmastar.it/news//business/sobi-riceve-offer-di-pino-per-81-mld-da-fondo-americano-36210).
As it happens, their drugs had been blocked by Ema in November 2020, which is now preparing to authorize Anakinra ….
“Sobi suffered a setback in November when an EMA commission reiterated its rejection of the investigational drug emapalumab to treat children with a rare inflammatory disease. The drug was approved for use in the United States as a first therapy for that disorder.Other candidates in the pipeline are for a form of gout, amyotrophic lateral sclerosis, and a rare blood disorder known as PNH.
The billionaire Wallenberg family, which is Sobi’s largest investor, is backing the deal. Investor AB, their investment vehicle, controls about 35% of the biotech company and said it would use the proceeds to reinvest in other companies. However, his agreement would lapse if another offer came to 251 crowns per share or more. “
Today the stock opened at 238 crowns and dropped to 236.
What will happen now? AIFA makes available the medicines anakinra, baricitinib and sarilumab for the treatment of COVID-19
https://www.aifa.gov.it/it/-/aifa-rende-disponibili-i-medicinali-anakinra-baricitinib-e-sarilumab-per-il-trattamento-del-covid-19
Will it therefore be possible to sell Sobi?
Our updates will follow.